Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Advanced BioMedical Technologies's enterprise value is $0.04 Mil.
Advanced BioMedical Technologies's EBITDA for the trailing twelve months (TTM) ended in Jul. 2021 was $-0.36 Mil. Therefore, Advanced BioMedical Technologies's EV-to-EBITDA for today is -0.12.
The historical rank and industry rank for Advanced BioMedical Technologies's EV-to-EBITDA or its related term are showing as below:
ABMT's EV-to-EBITDA is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 14.415 * Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Advanced BioMedical Technologies's PE Ratio (TTM) for today is calculated as:
Advanced BioMedical Technologies's share price for today is $0.0005.
Advanced BioMedical Technologies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jul. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.008.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Advanced BioMedical Technologies's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Advanced BioMedical Technologies EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Advanced BioMedical Technologies's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Advanced BioMedical Technologies's EV-to-EBITDA falls into.
Advanced BioMedical Technologies's current Enterprise Value is $0.04 Mil.
Advanced BioMedical Technologies's EBITDA for the trailing twelve months (TTM) ended in Jul. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.36 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Advanced BioMedical Technologies (ABMT) has a EV-to-EBITDA of -0.12 as of Aug. 01, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Advanced BioMedical Technologies.
Is Advanced BioMedical Technologies' EV-to-EBITDA too high?
Advanced BioMedical Technologies' current EV-to-EBITDA is -0.12.
How does Advanced BioMedical Technologies' EV-to-EBITDA compare to VYCO and ADMT?
Advanced BioMedical Technologies' EV-to-EBITDA of -0.12 can be compared against companies in the Medical Devices & Instruments industry. The industry median EV-to-EBITDA is 14.42. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.42, based on 510 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Advanced BioMedical Technologies. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Advanced BioMedical Technologies's current EV-to-EBITDA is -0.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Advanced BioMedical Technologies stock overvalued right now?
Advanced BioMedical Technologies (ABMT) has a current EV-to-EBITDA of -0.12. The current EV-to-EBITDA is -0.12. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Advanced BioMedical Technologies (ABMT), the current EV-to-EBITDA is -0.12 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Advanced BioMedical Technologies Inc is engaged in designing, developing, manufacturing, and the planned future marketing of self-reinforced, re-absorbable, biodegradable internal fixation devices. The company manufactures its products using Polyamide, and it is used in a variety of applications, which include orthopaedic trauma, sports-related medical treatment, cartilage injuries, and reconstructive dental procedures. Its Polyamide products include screws, rods, and binding wires consisting of enhanced fibres and high molecular polymers, which are designed to facilitate quick healing of complex fractures in many areas of the human skeletal system.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ABMT has been successfully added to your 
